New report highlights multiple targets for Invictus

|

Published 01-JUL-2019 13:00 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Invictus Energy Limited (ASX:IVZ) has released highly promising results from an Independent Report completed by Getech Group plc estimating substantial resource potential at its Cabora Bassa Project, located in the company’s 80% owned and operated SG 4571 Permit in Zimbabwe.

The Mzarabani Prospect has grown significantly in its scale and represents one of the largest conventional exploration targets globally.

The Independent Report by Getech has estimated the net mean recoverable conventional potential of the massive stacked Mzarabani prospect of 1.3 billion boe (barrels of oil equivalent) consisting of 6.5 Tcf (trillion cubic feet) and 200 million barrels of condensate net to Invictus.

The estimate for the primary Upper Angwa target within the Mzarabani Prospect has increased to 4.4 Tcf + 187 million barrels of conventional gas-condensate on a gross mean unrisked basis.

In addition, the newly identified Msasa Prospect, a new substantial structural prospect within SG 4571 which is also a stacked anticline feature, is estimated to contain 1.05 Tcf and 44 million barrels of conventional gas-condensate on a total gross mean unrisked basis.

The following provides a snapshot of Invictus’ gross unrisked estimated prospective gas and condensate resources, underlining the options open to it in terms of tapping into a variety of high profile exploration targets.

Invictus’ gross unrisked estimated prospective gas and condensate resources.

Recoverable potential of Mzarabani 1.3 billion boe

The updated estimate is the culmination of technical work over the last 12 months.

The substantial work undertaken to integrate the geological and basin modelling studies with the reprocessed and interpreted gravity, magnetic and seismic datasets has enabled Invictus to characterise the subsurface in more detail and identify and quantify the additional prospectivity.

The updated SG 4571 prospects and leads map.

This development has not only materially enhanced the value of the company’s acreage, but it has also de-risked it, an important aspect in terms of negotiating farmout agreements, attracting joint venture partners and raising capital.

Invictus’ understanding of the petroleum system in the Cabora Bassa Basin has been significantly enhanced as it has worked through new and improved data in recent months.

Appointment of farmout adviser

Invictus has engaged UK based ENVOI, a leading Acquisition and Divestiture adviser for the international upstream oil and gas industry, to run the farmout process for SG 4571.

The company has received significant industry interest ahead of the data room opening and is currently executing confidentiality agreements with several parties.

On the permitting front, Invictus has engaged the Scientific and Industrial Research and Development Centre (SIRDC) to conduct an Environmental Impact Assessment (EIA) of SG 4571.

The commencement of the EIA aims to ensure all necessary pre-drilling permits and activities are completed well ahead of schedule.

SIRDC has experience in carrying out EIAs of developmental projects in fields such as agriculture, mining, energy generation and construction projects.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X